Eli Lilly/$LLY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Ticker
$LLY
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
47,000
ISIN
US5324571083
Website
Eli Lilly Metrics
BasicAdvanced
$697B
63.13
$12.29
0.47
$5.60
0.77%
Price and volume
Market cap
$697B
Beta
0.47
52-week high
$972.53
52-week low
$677.09
Average daily volume
3.4M
Dividend rate
$5.60
Financial strength
Current ratio
1.372
Quick ratio
0.569
Long term debt to equity
218.243
Total debt to equity
243.609
Dividend payout ratio (TTM)
43.74%
Interest coverage (TTM)
22.79%
Profitability
EBITDA (TTM)
22,119.4
Gross margin (TTM)
81.70%
Net profit margin (TTM)
22.66%
Operating margin (TTM)
41.17%
Effective tax rate (TTM)
18.34%
Revenue per employee (TTM)
$1,040,000
Management effectiveness
Return on assets (TTM)
16.54%
Return on equity (TTM)
77.28%
Valuation
Price to earnings (TTM)
63.133
Price to revenue (TTM)
14.252
Price to book
46.64
Price to tangible book (TTM)
184.65
Price to free cash flow (TTM)
-1,043.815
Free cash flow yield (TTM)
-0.10%
Free cash flow per share (TTM)
-74.33%
Dividend yield (TTM)
0.72%
Forward dividend yield
0.77%
Growth
Revenue change (TTM)
36.38%
Earnings per share change (TTM)
80.99%
3-year revenue growth (CAGR)
18.67%
10-year revenue growth (CAGR)
9.61%
3-year earnings per share growth (CAGR)
22.24%
10-year earnings per share growth (CAGR)
19.61%
3-year dividend per share growth (CAGR)
15.22%
10-year dividend per share growth (CAGR)
10.61%
What the Analysts think about Eli Lilly
Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.
Bulls say / Bears say
Eli Lilly's acquisition of Verve Therapeutics for up to $1.3 billion enhances its gene-editing capabilities, potentially leading to innovative treatments for cardiovascular diseases. (reuters.com)
The development of orforglipron, an oral GLP-1 drug, has shown promising results in weight loss and blood sugar reduction, positioning Lilly to capture a significant share in the obesity treatment market. (reuters.com)
Analysts have raised Eli Lilly's stock price targets, citing strong performance of weight-loss drugs like Zepbound and Mounjaro, with Truist Securities increasing its target to $850. (thestreet.com)
Eli Lilly missed profit and revenue expectations in Q3 2024, leading to a stock decline of over 6% and a reduction in full-year profit guidance. (nbcnewyork.com)
The UK's NICE recommended against reimbursing Lilly's Alzheimer's drug, Kisunla, citing concerns over cost-effectiveness, which may impact its adoption and sales. (reuters.com)
Pfizer's withdrawal from developing a weight-loss pill due to safety concerns could intensify scrutiny on similar drugs, potentially affecting Lilly's weight-loss drug pipeline. (tipranks.com)
Data summarised monthly by Lightyear AI. Last updated on 21 Jun 2025.
Eli Lilly Financial Performance
Revenues and expenses
Eli Lilly Earnings Performance
Company profitability
Eli Lilly News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Aug15
Eli Lilly
Dividend·Ex-dividend
Sept10
Eli Lilly
Dividend·Payment
$1.50Per share
FAQs
What’s the current market cap for Eli Lilly stock?
Eli Lilly (LLY) has a market cap of $697B as of July 03, 2025.
What is the P/E ratio for Eli Lilly stock?
The price to earnings (P/E) ratio for Eli Lilly (LLY) stock is 63.13 as of July 03, 2025.
Does Eli Lilly stock pay dividends?
Yes, the Eli Lilly (LLY) stock pays dividends to shareholders. As of July 03, 2025, the dividend rate is $5.6 and the yield is 0.77%. Eli Lilly has a payout ratio of 43.74% on a trailing twelve-month basis.
When is the next Eli Lilly dividend payment date?
The next Eli Lilly (LLY) dividend payment is scheduled for September 10, 2025.
What is the beta indicator for Eli Lilly?
Eli Lilly (LLY) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.